Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Oral Relugolix for Androgen-Deprivation Therapy in Advanced ProstateCancer. Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostatecancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.In this phase 3 trial, we randomly assigned patients (...) with advanced prostatecancer, in a 2:1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks. The primary end point was sustained testosterone suppression to castrate levels (<50 ng per deciliter) through 48 weeks. Secondary end points included noninferiority with respect to the primary end point, castrate levels of testosterone on day 4, and profound castrate levels (<20 ng per deciliter) on day 15. Testosterone recovery was evaluated in a subgroup
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant ProstateCancer. Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostatecancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.In this double-blind, phase 3 trial, men with nonmetastatic (...) , castration-resistant prostatecancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily. Overall survival was assessed with a group sequential testing procedure and an O'Brien-Fleming-type alpha-spending function.As of October 15, 2019, a total of 288 of 933 patients (31%) in the enzalutamide group and 178
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk ProstateCancer: A Randomised, Open-label, Parallel-group The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk ProstateCancer: A Randomised, Open-label (...) Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk ProstateCancer: A Randomised, Open-label, Parallel-group Phase 2 Trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The Institute of Cancer Research and Royal Marsden Hospital, London, UK. Electronic address: firstname.lastname@example.org. 2 Urology San Antonio, San Antonio, TX, USA. 3 21st Century
of malignanttumors. UICC International Union Against Cancer. 8th edn. 2017. 73. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173: 1938. 74. Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of ProstaticCarcinoma. Am J Surg Pathol, 2005. 29: 1228 (...) as predictors for prostatecancer. J Clin Oncol, 2009. 27: 398. 133. Stephan, C., et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostatecarcinoma and benign prostate hyperplasia. Cancer, 1997. 79: 104. 134. Catalona, W.J., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostatecancer from benign prostaticdisease: a prospective multicenter clinical trial. JAMA, 1998. 279: 1542. 135
be offered as an alternative to conventional fractionation. The task force strongly encourages that these patients be treated as part of a clinical trial or multi-institutional registry. Comment: There is additional RCT evidence to support the recommendation of KQ3B that may increase the quality of evidence for the use of ultrahypofractionation in intermediate-risk disease from low to at least moderate . ENDORSED with comment KQ3C: In men with high-risk prostatecancer receiving EBRT, the task force (...) with the recommendations for information purposes. Guideline Endorsement 3-22 Section 2: Endorsement Methods Overview – April 28, 2020 Page 5 Selection of Guidelines The Radiation Treatment Program, Disease Pathway Management, Ontario GU Cancers Advisory Committee, GU disease site group (DSG) chairs reviewed the ASTRO, ASCO, and AUA evidence-based guideline on hypofractionated radiation therapy for localized prostatecancer and accepted it as potentially useful and relevant to guide practice in Ontario. Assessment
Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for ProstateCancer: A Systematic Review and Meta-analysis. The Prostate Imaging Reporting and Data System (PI-RADS) 3 score represents a "grey zone" that need to be further investigated to solve the issue of whether to biopsy these equivocal cases or not.To critically analyze the current evidence on PI-RADS 3 cases. We evaluated the prevalence of PI-RADS 3 cases in the literature and detection (...) rate of prostatecancer (PC) and clinically significant PC (csPC) at biopsy with regard to factors determining these rates.We searched in the Medline and Cochrane Library database from the literature from January 2009 to January 2019, following the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines.A total of 28 studies were included in our analysis (total number of PI-RADS 3 cases: 1759, range 20-187). The prevalence of PI-RADS 3 cases reported in available
Survival Rate of ProstateCancer in Asian Countries: A Systematic Review and Meta-Analysis. Prostatecancer is one of the most common health issues among men, especially older men. In recent years, incidences of prostatecancer is increasing.The aim of this study was to provide a comprehensive estimate of the survival of prostatecancer in Asian countries.We searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until June 1, 2018 (...) . The Newcastle-Ottawa Quality Assessment was used to evaluate the quality of selected papers. The review protocol was registered in PROSPERO (CRD42019117044).A total of 714 titles were retrieved. Thirty-seven studies met the inclusion criteria. Based on the random-effect model one-year, five-year and ten-year survival rate of prostatecancer were 81% (95% CI 77.8-84.2), 61.9% (95% CI 59.5-64.3) and 36.2% (95% CI 9.2-63.2) respectively. Survival rates based on HDI level for five-year were 30.07, 43.43
Nonsurgical Salvage Local Therapies for Radiorecurrent ProstateCancer: A Systematic Review and Meta-analysis. Different nonsurgical therapeutic strategies can be adopted for intraprostatic relapse of prostatecancer after primary radiotherapy, including re-irradiation (with brachytherapy [BT] or external beam radiotherapy [EBRT]), high-intensity focused ultrasound (HIFU), and cryotherapy. The main issues to consider when choosing nonsurgical salvage local therapies are local tumor control (...) and significant genitourinary toxicity.To conduct a systematic review and meta-analysis of the role of nonsurgical salvage modalities in patients with radiorecurrent prostatecancer and associated clinical outcomes and toxicity profiles.We performed a critical review of the Medline, Scopus, and ClinicalKey databases from January 1, 2000 through February 1, 2018 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified
Do prostatecancer-related mobile phone apps have a role in contemporary prostatecancer management? A systematic review by EAU young academic urologists (YAU) urotechnology group. To review the available literature regarding the use of prostatecancer-related mobile phone applications (PCA).The search was for English language articles between inceptions of databases to June 2019. Medline, EMBASE, Cochrane Library, CINAHL and Web of Science were searched. Full-text articles were reviewed (...) and do require further development before widespread integration into existing clinical practise. There are concerns with data protection, high readability standards and lack of information update in current PCAs. If developed appropriately with responsible governance, they do have the potential to play important roles in modern-day prostatecancer management.
Urinary microRNAs expression in prostatecancer diagnosis: a systematic review. Circulating microRNAs (miRNAs) have been shown to have the potential as noninvasive diagnosis biomarkers in several types of cancers, including prostatecancer (PCa). Urine-based miRNA biomarkers have been researched as an alternative tool in PCa diagnosis. However, few studies have performed miRNA detection in urine samples from PCa patients, as well as low numbers of miRNAs have been assayed, and there is a lack
Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostatecancer. To perform a systematic review and meta-analysis comparing overall prostatecancer detection rate and clinically-significant prostatecancer detection rate between MRI-ultrasound image guided fusion biopsy (MRI-US FB) and cognitive biopsy (CB).A systematic review of Pubmed, EMBASE, MEDLINE, and Cochrane library databases was performed. Identified studies were (...) assessed for clinical relevance and excluded based on a set of predefined criteria. Final articles included in the analysis comprised only prospective trials that compared CB vs. MRI-US FB in men with MRI-identifiable lesions (Prostate Imaging Reporting and Data System score 2+). Articles were reviewed for patient demographics, MRI protocol, and rates of overall and clinically significant prostatecancer detection by both modalities.Nine studies were analyzed. A composite 1,714 men with mean age 64.6
Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of ProstateCancer: A Systematic Review and Meta-analysis. Eur Urol 2019;76:284-303: Threshold Indicati 31980314 2020 04 22 1873-7560 77 5 2020 May European urology Eur. Urol. Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of ProstateCancer (...) : A Systematic Review and Meta-analysis. Eur Urol 2019;76:284-303: Threshold Indication for Magnetic Resonance Imaging-targeted Biopsy in the Detection of ProstateCancer. e134-e135 S0302-2838(20)30052-X 10.1016/j.eururo.2020.01.016 Kim Jae Heon JH Department of Urology, Soonchunhyang University Hospital, Soonchuhyang University Medical College, Seoul, Korea. Jeong In Gab IG Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address: igjeong
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced ProstateCancer: An International Multidisciplinary Systematic Review. The optimal treatment for men with high-risk localized or locally advanced prostatecancer (PCa) remains unknown.To perform a systematic review of the existing literature on the effectiveness of the different primary treatment modalities for high-risk localized and locally advanced PCa. The primary oncological outcome is the development (...) of the SPCG15 trial are known, the optimal local treatment remains a matter of debate. Patients should at all times be fully informed about all available options, and the likelihood of a multimodal approach including the potential side effects of both local and systemic treatment.We reviewed the literature to see whether the evidence from clinical studies would tell us the best way of curing men with aggressive prostatecancer that had not spread to other parts of the body such as lymph glands or bones
Re: Frank-Jan H. Drost, Daniel Osses, Daan Nieboer, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting ProstateCancer: A Cochrane Systematic Review and Meta-analysis 32089360 2020 04 22 1873-7560 77 5 2020 May European urology Eur. Urol. Re: Frank-Jan H. Drost, Daniel Osses, Daan Nieboer, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic (...) Biopsy for Detecting ProstateCancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol 2020;77:78-94: Are Targeted Prostate Biopsies Enough in Men with a Previous Negative Biopsy? e138-e139 S0302-2838(20)30116-0 10.1016/j.eururo.2020.02.010 Morote Juan J Department of Urology, Vall d'Hebron Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: email@example.com. Celma Anna A Department of Urology, Vall d'Hebron Hospital Campus, Universitat Autònoma de
Stereotactic Body Radiotherapy for Oligometastatic ProstateCancer Recurrence: A Meta-analysis. The purpose of this study was to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in oligometastatic prostatecancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) and local control (LC).Eligible studies were identified on Medline, Embase, and the Cochrane Library, and the proceedings of annual meetings through May 2019 (...) were also identified. A meta-regression analysis was performed to assess whether there is a relationship between BED and LC. In the univariate analysis, studies were separated by the study design, the number of metastatic sites, the site of metastases, radiotherapy machine, and prostate-specific antigen level at the time of SBRT. A P-value <0.05 was considered significant.Twenty-three observational studies with a total of 1441 lesions treated were included in the meta-analysis. The proportional